LMN 201
Alternative Names: LMN-201; LMN-Cdiff01Latest Information Update: 27 May 2024
At a glance
- Originator Lumen Bioscience
- Class Antibacterials; Enzymes; Proteins
- Mechanism of Action Bacterial toxin modulators; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Clostridium difficile infections
- Preclinical Crohn's disease; Ulcerative colitis
Most Recent Events
- 17 Oct 2023 Lumen Bioscience plans a phase II/III REPREVE trial for Clostridium difficile infections in the US in August 2024 (NCT05330182)
- 17 May 2023 LMN 201 receives Fast track status from the US FDA for Clostridium Difficile Infection
- 17 May 2023 LMN 201 receives Fast track status from the US FDA for Clostridium Difficile Infection (Prevention)